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Background: The effects of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers
(ARBs) on cardiovascular (CV) risk in hypertensive patients with type 2 diabetes mellitus (T2 DM) are uncertain. Our
objective was to analyze the effects of ACE/ARBs, on the incidence of myocardial infarction, stroke, CV events, and
all-cause mortality in hypertensive patients with T2 DM.
Method: PubMed and Embase databases were searched through January 2014 to identify studies meeting a priori
inclusion criteria and references in the published articles were also reviewed. Two investigators independently
extracted the information with either fixed-effect model or random-effect model to assess the effects of ACE/ARBs
treatment in hypertensive patients with T2 DM.
Results: Ten randomized controlled studies were included with a total of 21,871 participants. Overall, treatment with
ACE/ARBs in hypertensive patients with T2 DM was associated with a statistically significant 10% reduction in CV events,
pooled hazard ratio (HR) of 0.90 [95% confidence intervals (CI): 0.82-0.98] with no heterogeneity (I2 = 19.50%; P = 0.275);
and 17% reduction in CV mortality, pooled HR of 0.83 [95% CI: 0.72-0.96] with no heterogeneity (I2 = 0.9%; P = 0.388).
ACE/ARBs was not associated with MI, stroke and all-cause mortality.
Conclusions: Treatment with ACE/ARBs results in significant reduction in CV events and mortality in hypertensive
patients with T2 DM.Background
Hypertension and type 2 diabetes (T2 DM) frequently
coexist, and patients with this combination are at a higher
risk for cardiovascular (CV) events than those suffering
from hypertension or T2 DM alone [1-3]. Most (60% to
80%) people with T2 DM die of CV complications, and
up to 75% of specific CV complications have been at-
tributed to high blood pressure (BP) [4]. The improved
treatment of hypertension has been associated with a
marked reduction in death and hospitalization from CV
disease [5]. The use of angiotensin-converting enzyme
(ACE) inhibitors or angiotensin II receptor blockers
(ARBs), could reduce both CV morbidity and mortality* Correspondence: wangzengwu@foxmail.com
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unless otherwise stated.across populations that apart from hypertension [6-8],
had other co-morbid conditions.
The beneficial effect of ACE inhibitor treatment on all-
cause mortality for hypertensive patients was well estab-
lished in a recent meta-analysis [9]. However, the effect of
ACE/ARBs on CV risk in hypertensive patients with T2
DM remains controversial. The Heart Outcomes Preven-
tion Evaluation (HOPE) study showed that treatment with
Ramipril reduced cardiovascular events in patients with dia-
betes, out of which 56% were hypertensive [10]. The Fosino-
pril Versus Amlodipine Cardiovascular Events Randomized
Trial (FACET) and Captopril Prevention Project (CAPPP)
study demonstrated that the ACE inhibitors fosinopril could
significantly reduce risk of major vascular events in hyper-
tensive diabetic patients compared with controls [11,12].
However, other studies like the Irbesartan Diabetic Nephrop-
athy Trial (IDNT) or The Action in Diabetes and Vascular
disease: preterAx and diamicroN-MR Controlled Evaluation. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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hypertensive patients with T2 DM [13,14].
To our best knowledge, there is no meta-analysis or RCT
focused on the effect of ACE/ARBs on CV risk in hyperten-
sive patients with T2 DM, although these classes of drug
were recommended for these patients by the guidelines of
2013 European Society of Hypertension (ESH) and of the
European Society of Cardiology (ESC) and the eighth report
of Joint National Committee (JNC 8) [15,16]. However, the
evidence derived from papers focused on the Individuals
with and without Diabetes Mellitus separately [6].
The objective of the present study is to review random-
ized clinical trials (RCT) were revising the effect of antihy-
pertensive treatment using ACE/ARBs on incidence of
myocardial infarction (MI), stroke, CV events, and all-cause
mortality in hypertensive patients with T2 DM.Figure 1 Flow chart of study selection.Methods
Search strategy and study selection
We performed a systematic search of Pubmed and Embase
databases through January 2014 for relevant studies per-
formed in hypertensive patients with T2 DM. Subject head-
ings and key words used for the literature search were as
follows: 1) mortality, CV diseases, MI and stroke; 2) hyper-
tension and diabetes; 3) angiotensin-converting enzyme
inhibitors and angiotensin receptor blockers; 4) RCTs. The
titles, abstracts and full-texts were reviewed independently
by two reviewers. The criteria for eligible studies were as
follows: 1) Randomized clinical trials in hypertensive pa-
tients with T2 DM comparing active treatment with ACE
inhibitors or ARBs with control treatment (placebo, life
style changes, active antihypertensive treatment with drugs
other than ACEI or ARB); 2) The endpoints were mortality,
CV events, MI or stroke; 3) Hazard ratios (HR) were calcu-
lated with the corresponding confidence intervals (CI). Fol-
lowing this search, references of published articles were
also reviewed. Finally, 10 RCTs were selected, out of them,
IDNT data was used in two articles for the analysis of
different endpoint events [14,17] (Figure 1).Data extraction
We collected the following information from each study:
first author name or study title, year of publication,
country of origin, gender, follow-up period, class of anti-
hypertensive drugs, disease outcome, the number of trial
participants, HR with the corresponding 95% CI, and the
mean diastolic and systolic BP at baseline. Two investiga-
tors independently calculated and tabulated the data using
a standard extraction formula. Any discrepancies were
discussed by the research team and were resolved. In
addition, we used the modified Jadad scale to determine
the quality of the studies [18].Endpoint definition
The endpoints of this pooled analysis were MI, stroke, CV
events, and CV and all-cause mortality. Stroke including
fatal or nonfatal stroke, MI including fatal or nonfatal acute
MI, and CV events is according to trial-specific definitions,
including coronary artery bypass, percutaneous translumi-
nal coronary angioplasty, death from cardiovascular causes,
nonfatal myocardial infarction, heart failure, etc. Not all
studies included every endpoint. Data on all-cause mortal-
ity were available in 7 trials, CV mortality in4 trials, CV
events in 8 trials, MI in 5 trials, and stroke in7 trials.
Statistical analysis
The combined risk estimates were computed with either
fixed-effect model or random-effect model, if hetero-
geneity existed. The Cochrane Q statistics (significance
level of P < 0.10) and the I2 statistics were used to assess
the heterogeneity of HR across studies. Since the character-
istics were not consistent from study-to-study, we further
conducted sensitivity analysis and stratified analyses to
explore the possible explanation for heterogeneity. For
sensitivity analysis, the effect of a single study on overall
risk factors was investigated by omitting one study at a
time. Stratified analyses were performed by control group
(placebo-controlled or active antihypertensive drugs, base-
line systolic BP, reduction of systolic BP, and class of anti-
hypertensive drugs (ACE inhibitors or ARBs). The possibility
of publication bias was assessed using the Begg and Egger
test. We also performed the visual inspection of Begg funnel
plots in which log RRs were plotted against their SEs. All
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(Stata Corp LP, College Station, TX). A value of P < 0.05
was defined as statistically significant.
Results
Characteristics of the studies
Table 1 shows the 10RCTs’ characteristics of 21,871 hyper-
tensive patients with T2 DM, published between 1998 and
2012. Two RCTs were conducted in the United States
[11,17], 3 in Europe [12,19,20], 2 in Japan [21,22], and 3
were multicenter studies [13,14,23]. IDNT data was used in
two articles for the analysis of different endpoint events
[14,17]. The length of follow-up ranged from 2.5 to 9 years.
All studies were conducted in hypertensive patients
with T2 DM except for one (the respondents were
diabetics, 59% of those were hypertensive) [13]. The
number of respondents ranged from 257 to 11,140
(total 21,871) participants. BP decreased more in ACE/
ARBs group (mean difference: systolic BP 4.14 mm Hg
and diastolic BP 1.63 mmHg) compared with those
assigned to control treatment. Study quality generally
was good (Additional file 1: Table S1).
All-cause mortality
Treatment with ACE/ARBs did not reduce significantly
all-cause mortality (HR: 0.91, 95% CI: 0.83-1.00, P = 0.062);
the degree of heterogeneity in the treatment effect across
all trials was low (I2 = 21.0%) and non-significant (P = 0.210,
Figure 2a).
CV mortality
Treatment with RAAS achieved a 17% significant reduction
in CV mortality (HR: 0.83, 95% CI: 0.72-0.96, P = 0.012),
the degree of heterogeneity in the treatment effect across
all trials was low (I2 = 0.9%) and non-significant (P = 0.388,
Figure 2b).
MI and stroke
In all 5 trials grouped together, MI risk was not reduced
significantly (HR: 0.85, 95% CI: 0.53-1.37, P = 0.511), with a
higher heterogeneity across all trials (I2 = 66.5%, P = 0.018,
Figure 2c). In all 8 trials grouped together, we did not find
a statistically significant reduction in stroke with ACE/
ARBs treatment (HR: 0.99, 95% CI: 0.85-1.15, P = 0.855);
the degree of heterogeneity in the treatment effect across
all trials was low (I2 = 0.0%) and non-significant (P = 0.745,
Figure 2d).
CV events
In all 8 trials grouped together, treatment with ACE/
ARBs was associated with a statistically significant 10%
significant reduction in CV events (HR: 0.90, 95% CI:
0.82-0.98, P = 0.019), with non-significant heterogeneity
between studies (I2 = 19.50%, P = 0.275, Figure 2).Stratified and sensitivity analysis
For stratified analysis of key characteristics see Additional
file 1: Table S2. Exclusion of any single study did not sub-
stantially alter the result in analysis of different endpoints.
Publication bias
The funnel-plot asymmetry, and the P-values using an
Egger regression test were 0.97 (all-cause mortality), 0.41
(CV events), 0.81 (CV mortality), 0.80 (MI) and 0.55
(stroke), indicating no evidence for publication bias.
Discussion
Although the ESH/ESC and JNC8 [15,16] recommend
ACE inhibitors or ARB as the preferred therapy in hyper-
tensive patients with T2 DM, the effect of ACE/ARBs on
mortality in hypertensive patients with T2 DM remains not
unequivocally accepted. In an effort to evaluate the effects
of ACE/ARBS on CV outcomes in hypertensive patients
with T2 DM, we performed a systematic review of the
literature and analyzed 10 RCTs. Overall, the results of our
review showed that treatment with the ACE/ARBs was
associated with a 10% reduction in CV events and, 17%
reduction in CV mortality. Previous studies and meta-
analyses evaluating the effects of ACE/ARBs on the overall
risk for CV events in hypertensive patients have yielded
conflicting results. The Asia Pacific Cohort Studies Collab-
oration (APCSC) study indicated that major CV risk was
reduced to a comparable extent in hypertensive individuals
with or without diabetes while on an ACE inhibitor-based
treatment, or other antihypertensive regimens [24]. The
NAVIGATOR Study also failed to find a reduction of CV
risk in patients with impaired glucose tolerance and estab-
lished CV disease using valsartan and lifestyle modification
[25]. On the other hand, in another study [26], initiation of
antihypertensive treatment involving ACE inhibitors in
hypertensive patients and with 8% T2 DM, appeared to
lead to better outcomes than treatment with diuretic
agents. A recent meta-analysis showed that ACE/ARBs
were associated with a 5% reduction in all-cause mortality
and a 7% reduction in CV mortality; the treatment effect
resulted entirely from the class of ACE inhibitors. No mor-
tality reduction could be demonstrated with ARB treat-
ment in the hypertension population [9]. Bangalore and
colleagues pooled 37 RCTs and showed that ARBs reduce
the risk of stroke, heart failure, and new onset diabetes
compared with controls in general hypertensive [27]. In
our study, we could not ascertain whether the observed
reduction in CV events (10%) and reduction in CV mor-
tality (17%) among hypertensive patients with T2DM
could be was attributed to treatment with ACE inhibitors
or treatment with ARBs.
In our meta-analysis, beneficial effects were only found
in ADVANCE (for CV and all-cause mortality), FACET
(for CV event) and CAPPP (for CV mortality and MI)
Table 1 Baseline characteristics of study population in 10 trials
Study/author Public year Country Age (year) Total (I/C)* Female (%) follow-up years Medications used (I/C)* BP (mmHg) I(SBP/DBP;
C(SBP/DBP
Reduction of BP (mmHg)#
I(SBP/DBP; C(SBP/DBP)
UKPDS [19] 1998 United Kingdom 56 400/358 48 over 9 Captopril/Atenolol 159/94; 159/93 15/10; 16/12
FACET [11] 1998 United State 63 189/191 41 2.5-3.5 Fosinopril/Amlodipine 170/95; 171/94 19/8; 13/8
RENAAL [23] 2001 Multi-centers 60 751/762 37 3.4 Losartan/Placebo 152/82; 153/82 12/8; 11/8
CAPPP [12] 2001 Sweden/Finland 25–66 309/263 38 6.1 Captopril/Conventional drugs 164/97; 163/97 8/4; 10/5
IDNT [14,17]& 2001/2003 Multi-centers 30-70 579/569 32 2.6 Irbesartan/Placebo 160/87; 158/87 20/10; 16/7
ADVANCE [13] 2007 Multi-centers 66 5,569/5,571 43 4.3 Perindopril/Placebo 145/81; 145/81 5.6/2.2#
CASE-J [21] 2010 Japan 64 1,011/1,077 44 3.3 Candesartan/Amlodipine 160/88; 160/88 —
DEMAND [20] 2011 Italy/Slovenia ≥40 127/127 37 3.8 Delapril/Placebo 147/87; 147/88 11/6; 9/5
NHS [22] 2012 Japan 63 575/575 34 3.2 Valsartan/Amlodipine 145/82; 144/81 14/9; 13/8
UKPDS = United Kingdom Prospective Diabetes Study Group, FACET = Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial, RENAAL = Reduction of Endpoints in NIDDM with the Angiotensin II
Antagonist Losartan, CAPPP = The Captopril Prevention Project, IDNT = Irbesartan Diabetic Nephropathy Trial, ADVANCE = The Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation,
CASE-J = candesartan antihypertensive survival evaluation in Japan, DEMAND = Delapril and Manidipine for Nephroprotection in Diabetes, NHS = NAGOYA HEART Study.
*I/C = Intervention/Control, SBP = systolic blood pressure, DBP = diastolic blood pressure; #reduction of SBP/DBP in intervention group compared with in placebo; –— not give detail information; &IDNT data was used in two




















Figure 2 All-cause mortality (a), CV mortality (b), MI (c), stroke (d), and CV events (e) treatment effect of ACE/ARBs in all included trials.
CV = cardiovascular, MI = myocardial infarction, HR = hazard ratio, CI = confidence interval.
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However, stratified analysis of all-cause mortality and CV
events failed to find an association both with the ACE
inhibitor group and the ARB group.
There was marginal statistically significant effect of ACE/
ARBs on the all-cause mortality in hypertensive patients
with T2DM (P = 0.062). A recent meta-analysis also found
the ACEIs significantly reduced the risk of all-cause
mortality by 13% in diabetes [28]. More studies should be
performed to confirm the effect of ACEI/ARBs in hyper-
tensive patients with T2DM.
The beneficial effect on CV events might be attributed
mainly to differences in systolic BP [29]. In the Systolic
Hypertension in the Elderly Program (SHEP) study, elderly
persons with T2 DM derived more benefit from aggressive
systolic BP lowering in reduction of CV than those without
diabetes [30]. Additional benefit of aggressive BP lowering
in the diabetic population was observed in a sub-analysis
of Systolic Hypertension in Europe (SystEur) Trial. In that
trial, although systolic BP was reduced by a comparable
amount in each group, the risk reduction in mortality from
CV disease was 13% in non-diabetic patients versus 76%
for the diabetic patients [31]. There is weaker evidence that
the effect of BP lowering between different drug classes is
varied. Law and colleagues [32] pooled 354 RCTs and
found that ACE inhibitors, calcium antagonists, and five
categories of drug produced similar reductions in BP. We
did not find a significant effect of BP lowering in stratified
analysis, which may be due to lower statistical power.
Therefore, further specific RCTs need to be performed to
evaluate the BP lowering effect of Various ACE/ARBs in
hypertensive patients with T2DM.
Several limitations of our analysis have to be mentioned.
Firstly, our results are subject to limitations inherent to
any meta-analysis based on pooling of data from different
trials, including use of different definitions for CV events,
different dosages of the active and control drug, different
follow-up times, optimal BP target, combination treat-
ment and participants with other concomitant conditions
or background therapy. Although we could not find a
differential result in sensitivity or stratified analyses, it was
impossible to accurately estimate the effect of ACE/ARBs
in patients with T2 DM. Secondly, one study did not
report HR with 95% CI when a significant result was
found [33] and it was not included in our analysis. This
issue probably resulted in an underestimation of the effect
of ACE/ARBs.
Conclusion
This meta-analysis, which involved almost 21,871 hyper-
tensive patients with T2 DM, demonstrated that ACE/ARBs
as a class of antihypertensive drugs were associated with a
significant 10% reduction effect of CV events and 17%
reduction in CV mortality when compared with control oractive antihypertensive regimens with drugs other than
ACEI or ARB. Stratified subgroup analysis according to
class of BP-lowering regimens and different control group
failed to differentiate between ACE inhibitors or ARB
effect on CV outcomes. More studies should be per-
formed to clarify if the beneficial effect on CV events and
CV mortality among hypertensive patients with T2DM
was derived from ACEIs, or ARBs.
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